Investigation of the Ovarian and Prostate Cancer Peptidome for Candidate Early Detection Markers Using a Novel Nanoparticle Biomarker Capture Technology
Journal Title: The AAPS Journal - Year 2010, Vol 12, Issue 4
Abstract
Current efforts to identify protein biomarkers of disease use mainly mass spectrometry (MS) to analyze tissue and blood specimens. The low-molecular-weight “peptidome” is an attractive information archive because of the facile nature by which the low-molecular-weight information freely crosses the endothelial cell barrier of the vasculature, which provides opportunity to measure disease microenvironment-associated protein analytes secreted or shed into the extracellular interstitium and from there into the circulation. However, identifying useful protein biomarkers (peptidomic or not) which could be useful to detect early detection/monitoring of disease, toxicity, doping, or drug abuse has been severely hampered because even the most sophisticated, high-resolution MS technologies have lower sensitivities than those of the immunoassays technologies now routinely used in clinical practice. Identification of novel low abundance biomarkers that are indicative of early-stage events that likely exist in the sub-nanogram per milliliter concentration range of known markers, such as prostate-specific antigen, cannot be readily detected by current MS technologies. We have developed a new nanoparticle technology that can, in one step, capture, concentrate, and separate the peptidome from high-abundance blood proteins. Herein, we describe an initial pilot study whereby the peptidome content of ovarian and prostate cancer patients is investigated with this method. Differentially abundant candidate peptidome biomarkers that appear to be specific for early-stage ovarian and prostate cancer have been identified and reveal the potential utility for this new methodology
Authors and Affiliations
Claudia Fredolini, Francesco Meani, Alessandra Luchini, Weidong Zhou, Paul Russo, Mark Ross, Alexis Patanarut, Davide Tamburro, Guido Gambara, David Ornstein, Franco Odicino, Monica Ragnoli, Antonella Ravaggi, Francesco Novelli, Devis Collura, Leonardo D’Urso, Giovanni Muto, Claudio Belluco, Sergio Pecorelli, Lance Liotta, Emanuel F. Petricoin, III
Keywords
Related Articles
- EP ID EP681414
- DOI 10.1208/s12248-010-9211-3
- Views 77
- Downloads 0
The potential use of raman mapping to investigate in vitro deposition of combination pressurized metered-dose inhalers
Scanning near-infrared Raman microscopy has been used to map aerosol particulate deposits produced from pressurized metered-dose inhalers (pMDI). A commercially available combination asthma therapy pMDI (Ventide, Allen a...
Editorial: Theme issue “Drug addiction—From basic research to therapies”
The Pharmacokinetic/Pharmacodynamic Pipeline: Translating Anticancer Drug Pharmacology to the Clinic
Progress in an understanding of the genetic basis of cancer coupled to molecular pharmacology of potential new anticancer drugs calls for new approaches that are able to address key issues in the drug development process...
Commentary: Current Perspectives on the Aggregation of Protein Drugs
Paracellular Tightness and Claudin-5 Expression is Increased in the BCEC/Astrocyte Blood–Brain Barrier Model by Increasing Media Buffer Capacity During Growth
Most attempts to develop in vitro models of the blood–brain barrier (BBB) have resulted in models with low transendothelial electrical resistances (TEER), as compared to the native endothelium. The aim of the pre...